PRX002

Prothena Biosciences Limited · Phase 1 active Small molecule

At a glance

Generic name	PRX002
Sponsor	Prothena Biosciences Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PHASE2)
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease (PHASE1)
Single Ascending Dose Study of PRX002 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PRX002 CI brief — competitive landscape report
PRX002 updates RSS · CI watch RSS
Prothena Biosciences Limited portfolio CI